July 29, 2020 – Amgen Korea, a leading company in biotechnology, today announced that it successfully ended the third Amgen Science Academy – Real World Evidence symposium between July 24 and 25, where it invited nearly 300 healthcare professionals, from home and abroad, to discuss the development and use of real world evidence in medical science.
The Amgen Science Academy is a symposium led by Amgen Medical Department to facilitate discussions on the unlimited possibility of life science based on the scientific capabilities of Amgen and suggest a direction for the development and use of innovative medicines. Launched in 2018, the annual medical symposium celebrates the third anniversary this year. The central themes that have been addressed in the past include monoclonal antibody for the first symposium and genetics for the second. This year, discussions have centered on the development and value of real-world evidence, how to develop them for specific use, and various approaches in their use. The symposium took the form of a large-scale virtual event to help healthcare professionals and international speakers to join the event from many more regions and exchange diverse opinions and views regardless of their locations and schedules.
The first day of the symposium was spared for checking the value and opportunities in the use of real -world evidence with local and international experts. Dr. Jeff Lange, Director, Center for Observational Research, Amgen JAPAC, introduced the company’s successful cases of using real world evidence to advance the development and authorization of new drugs. Professor Shin Ju-young from Sungkyunkwan University shared the value and opportunities in the use of real-world evidence and future aspiration in Korea. Then, Professor Eric David Peterson from Duke University presented the use of registries as the foundation of real-world evidence and their significance in clinical decision making process.
The second day started with a keynote speech from Brian Bradbury, Vice President and Head, Center for Observational Research, Amgen Global, who explained how to develop credible and valuable real-world evidence. He said that the use of real-world data in pharmaceutical research and development could improve the credibility of real-world evidence since there are limits in data from clinical trials to ensure the safety of a drug. He then emphasized that a platform resulting from this approach would have a clear merit not only in the drug discovery and development process but also in other research areas, such as diseases, treatment patterns and standard of care. Also, he said that Amgen has already made the best use of real-world evidence in presenting the grounds that meet the regulatory bases, leading to the faster delivery of better treatment options to patients. In the following speech, Dr. Erich Wohlhieter, Executive Director, Digital Health and Innovation, Amgen Global, spoke about how to harness the power of the state-of-the art technologies, such as artificial intelligence, machine learning and big data analytics, in generating real world evidence.
“With medical information being collectible in a digital format, the value and opportunities in the use of real-world evidence is expanding and taking higher priority among regulatory authorities, including FDA,” said Dr. Victoria Elegant, Vice President, Medical, Amgen JAPAC. “As we have already made the best use of real world data not only in the drug authorization procedures but also in the expansion of indication, the design of clinical study and the confirmation of safety since a decade ago, it was meaningful for us to host this year’s Amgen Science Academy as a venue for in-depth discussions with healthcare professionals in Korea about substantial opportunities in the use of real world evidence.”
“Amgen’s effort to bring a breakthrough treatment to therapeutic areas where treatment options are limited or not available has built on our biology and genetics-first strategy in research and development to maximize our scientific capabilities,” said Sang Noh, General Manager, Amgen Korea. “With the annual Amgen Science Academy, we have tried to develop discussions beyond certain therapeutic areas towards various scientific topics that can be comprehensively applied to research endeavors in medical science. This year, we invited healthcare professionals into a large-scale virtual symposium as we now live in the new normal. Amgen Korea will continue to host various symposiums for medical science as a way to fulfill our mission—to serve patients.”
# # #
This media release was prepared to provide information on Amgen’s general business activities. Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.
# # #
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
About Amgen Korea
Amgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.
We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
Min-Jung Jung (email@example.com)